Abstract
To analyze therapeutic strategies utilization and resources consumption in patientsaffected by Crohn Disease (CD) or Ulcerative Colitis (UC) in an Italian real-worldsetting, Veneto Region. An observational retrospective cohort analysis of administrative databases of Veneto Region was performed. Patients with a hospitalization discharge diagnosis of MC or UC (ICD-9-CM codes: 555-556) or exemption code for CD or UC (codes:009.555–009.556) from 01/01/2011 to 30/09/2016 (inclusion period) were included. The index-date (ID) was the 1stbiologic agent prescription during the inclusion period. This study refers to patients naive to index biological agent during the inclusion period.All patients were characterized 12 months prior the ID and followed up after the ID for 9 months (Follow-up, F-up). We identified 18,133 patients with a diagnosis of MC or UC; mean age was 52.3 and 54.8% were males. CD and UC prevalence in the study population was estimated at 0.4% (denominator= 4,937,854). A total of933 were naïve to index biological agent; among them, 495 patients were treated with infliximab, 370 with adalimumab, 51 with golimumab and 17 with vedolizumab. It is important to mention that infliximab is tracked in our database starting from 2015 and vedolizumab starting from May 2016.The percentage of patients who required dose escalation, during F-up, was: 12.4% for adalimumab, 13.7% for golimumab, 7.3% for infliximab and none for vedolizumab. During the F-up, the percentage of patients who switched their ID therapy was: 5.7% for adalimumab, 15.7% for golimumab, 6.9% for infliximab and none for vedolizumab. Per patient disease cost at one year, was: €12,242 for adalimumab, €12,630 for golimumab, €10,203 for infliximab, €10,875 for vedolizumab. Our study is still ongoing. Given the limited patients in this early phase of study, the results are not conclusive yet. Final and detailed analysis will be presented at the end of the study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
